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Introduction 
Eosinophils are inflammatory cells which are 
believed to play a key role in a variety of inflamma- 
tory conditions, including parasitic and allergic dis- 
eases. These cells are cytotoxic to parasites and 
mammalian cells, and can modulate the function of 
other cells. After activation, they are able to produce 
and release lipid-derivatives, oxygen free radicals 
and cytotoxic-granule-derived proteins. The presence 
of these eosinophilic cationic proteins, including 
eosinophil cationic protein (ECP), major basic pro- 
tein (MBP), eosinophil peroxidase and eosinophilic 
protein X (EPX, also called eosinophil-derived 
neurotoxin), in biological fluids or inflammatory 
tissues is accepted as a marker of eosinophilic 
activation (1). 
Although a high number of eosinophils are found 
both in the peripheral circulation and the broncho- 
alveolar lavage (BAL) fluid of patients with eosino- 
philic pneumonia, little is known about the extent of 
eosinophil degranulation encountered in this dis- 
order. The present case report describes a patient 
with eosinophilic pneumonia in whom high serum 
levels of both ECP and EPX were observed, as well as 
a high level in the BAL fluid, indicating that marked 
eosinophil degranulation had taken place. 
Materials and Methods 
CASE REPORT 
A 63-year-old woman presented with a 6-month 
history of productive cough, night sweats, lethargy 
and dyspnoea with wheezing. The illness had started 
a few weeks after returning from a safari in Kenya, 
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Africa, and did not improve after symptomatic treat- 
ment and administration of antibiotics. Family 
history for asthma and atopic disorders was negative. 
Past medical history and environmental or medi- 
cation exposure were not contributory. The patient 
did not take L-tryptophan-containing substances. 
She had no fever. Physical examination was normal 
apart from widespread inspiratory crackels. 
A chest radiograph revealed dense infiltrates in 
both lower lobes. A computed tomographic (CT) 
scan of the chest showed patchy alveolar bilateral 
opacities. Laboratory values on admission included 
an elevated erythrocyte sedimentation rate of 
54mmh-’ (normal values O-20 mm h ~ ‘). The 
white blood cell number was 17 000 mm-’ (normal 
values 4300-10 000 mnp3) with a 55% increase 
of eosinophils (absolute eosinophil count of 
9420 mm - 3; normal < 600 mm - 3). Pulmonary func- 
tion tests revealed a normal airway resistance, with a 
decreased vital capacity (50% of predicted) and total 
lung capacity (74% of predicted). An arterial blood 
gas analysis showed hypoxaemia (PaO,: 63 mmHg) 
with normocapnia. 
There was no serologic evidence for recent expo- 
sure to fungi, mycoplasma, viruses, parasites or 
Chlamydia psittaci. Cultures of blood, urine, sputum 
and BAL fluid (see below) for viruses, bacteria, fungi 
and mycobacteria were negative. Antinuclear anti- 
bodies were normal. Stool cultures for ova and 
parasites were negative. Precipitating antibodies 
against fungi or avian serum were not present. 
BRONCHOALVEOLAR LAVAGE 
Fibre-optic bronchoscopy with BAL was per- 
formed to rule out infection before treatment was 
initiated. After local anaesthesia, the fibre-optic 
bronchoscope was inserted through the nose and 
wedged in a distal portion of a segmental bronchus at 
the site of maximal infiltrate. Three 50 ml aliquots of 
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Table I Sequential serum levels of eosinophilic cationic 
protein (ECP) and eosinophil-derived neurotoxin (EPX) in 
a case of eosinophilic pneumonia before and after treatment 
with methylprednisolone 
Hours Eosinophils 
after ECP* EPXt Eosinophils (abs. number 
Day treatment &g l- ‘) &g I- ‘) (%) mmm3) 
1 - 170 949 53 7420 
5 - 281 1383 65 8515 
7 ~ 245 2116 50 6484 
7 3 47 199 21 1734 
7 6 43 161 8 512 
7 9 30 127 3 204 
8 24 71 319 22 2376 
11 96 40 181 17 1802 
12 120 30 117 6 679 
360 ~ 17 21 8 200 
Normal values: *<20 pg 1~ I; 18-40 pug 1~ r. 
0.9% saline were instilled through the bronchoscope. 
Eosinophils made up 96% of the cells recovered. 
Numerous eosinophils were present around bron- 
chioles in a transbronchial biopsy. No granulomas 
were detected. 
TREATMENT 
The patient was started on a course of 
intravenously administered methylprednisolone 
(SOLUMEDROLm, Upjohn) at a dose of 
1 mg kg ~ r for 5 days. This resulted in a dramatic 
improvement of the clinical condition of the patient, 
clearing of the chest X-ray and a rapid drop of the 
blood eosinophil count (Table 1). She was discharged 
from the hospital in good clinical condition after 
5 days of treatment, when the intravenous route was 
changed into oral methylprednisolone (32 mg). She 
has been followed in another hospital for more than 
1 yr with no evidence of relapse, after tapering the 
corticosteroids over a period of 8 weeks. A blood 
smear taken exactly 1 yr after the initial admission 
showed a number of neutrophils within the normal 
range and 8% eosinophils (normal O-5%). Pulmonary 
function tests 1 yr after treatment were normal. 
MEASUREMENT OF MARKERS OF EOSINOPHIL 
DEGRANULATION 
Levels of ECP and EPX in serum and BAL fluid 
were determined using a double-antibody radio- 
immunoassay (Pharmacia Diagnostics AB, Uppsala, 
Sweden), with results expressed in pg 1 - I. To obtain 
serum, venous blood was collected in SST tubes and 
allowed to clot at room temperature for 60 min, 
centrifuged at 1350 g for 10 min and then stored at 
- 70°C. Assay sensitivity for ECP and EPX was 
2pgl-’ and 3pgl-‘, respectively. Cross-reactions 
for both proteins between the two tests used was 
~0.03%. Serum from three healthy volunteers and 
sequential samples taken from an asthmatic patient 
were used as control serum samples, and processed in 
an identical way to that described above. Broncho- 
alveolar lavage fluid obtained from two healthy con- 
trol patients, two patients with bacterial pneumonia 
(intubated on intensive care, isolation of Eschericha 
coli in both patients), two patients with bronchial 
asthma (stable on inhalation glucocorticoids) and 
two patients with full-blown adult respiratory distress 
syndrome (ARDS, intubated and ventilated on inten- 
sive care) were also assessed for the presence of these 
eosinophil markers. The same BAL procedure of 
3 x 50 ml was used for all patients and controls. The 
first sample was discarded to avoid bronchial con- 
tamination. For all patients, ECP and EPX were 
measured in the pooled volumes recovered after 
instillation of the second and third 50 ml aliquot. All 
samples were analysed in duplicate. 
Results 
SERUM 
In the three healthy volunteers studied, levels of 
ECP (median 11.0 gg 1~ ‘, range 4.7-16.5 pug 1~ ‘) 
and EPX (median 37.4pg111, range 14.55 
37.6pg I- ‘) were observed well within the range 
reported for healthy volunteers. Very high serum 
levels for both EPX and ECP were observed in the 
patient with hypereosinophilia before treatment was 
initiated (Table 1). Some samples had to be diluted to 
fall within the range of detection of the assay. Serum 
levels of both ECP and EPX declined rapidly 
after initiation of treatment with corticosteroids, 
accompanied by a rapid decline in the number of 
eosinophils in the peripheral circulation (Table 1). 
When all serum samples of this patient were pooled, 
there was an excellent correlation between the 
number of circulating eosinophils and both the ECP 
levels (r=0.883, P=O.OOl) and the EPX levels 
(v=O.867, P=O.OOZ), as well as between the ECP and 
EPX levels (v=O.967, P<O.OOOl). 
BRONCHOALVEOLAR LAVAGE 
The BAL sample of the patient with eosinophilic 
pneumonia had to be diluted (1110 and l/100 with the 
buffer supplied by the manufacturer) to fall within 
the range of detection for both the ECP 
(22200 pug 1 - ‘) and EPX (3-400 pug 1~ ‘) assay 
(Table 2). Parallelism between the two different steps 
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Table 2 Bronchoalveolar lavage (BAL) fluid levels of 
eosinophilic cationic protein (ECP) and eosinophil-derived 
neurotoxin (EPX) in individuals from different patient 
groups 
Diagnosis 
Eosinophils in ECP EPX 
BAL fluid (%) @g l- ‘) (ug l- ‘) 
Eosinophilic pneumonia 96 856.6 677.1 
Normal volunteer 1 <2 <3 
Normal volunteer 0 <2 11.0 
Bacterial pneumonia 1 4.1 11.8 
Bacterial pneumonia 0 <2 5.0 
Asthma 2 <2 <3 
Asthma 2 <2 <3 
ARDS 1 17.5 29.5 
ARDS 1 6.5 9.0 
ARDS=adult (acute) respiratory distress syndrome. 
of dilution was observed. Lower levels were observed 
for the BAL fluid of the two ARDS patients investi- 
gated. No ECP was detected in the BAL fluid 
recovered from the control subjects and asthmatic 
patients (Table 2). 
Discussion 
This case report describes a patient with marked 
peripheral and bronchoalveolar eosinophilia. As no 
cause of the eosinophilia was found, the diagnosis of 
idiopathic eosinophilic pneumonia was made based 
on the profile of the BAL cells, radiographic pattern 
of the chest and the clinical presentation (2). Other 
causes of an increased percentage of eosinophils in 
BAL were excluded (3), including interstitial lung 
disease, AIDS-associated pneumonia and drug- 
induced lung disorders. Moreover, the authors report 
on the very high levels of eosinophil granular pro- 
teins in both the serum and BAL fluid of this patient. 
Given the paucity of other inflammatory cells in the 
BAL fluid and the fact that most other inflammatory 
cells are known not to contain these proteins, the 
authors postulate that these cytotoxic compounds 
were released by the eosinophils. 
The recognition of so-called hypodense eosinophils 
in eosinophilic pneumonia suggests that eosinophils 
are at least partially degranulated, and appear to 
be activated in this condition (4). However, only 
limited data are available regarding to what extent 
eosinophils release these proteins in patients with 
eosinophilic pneumonia. To the authors’ knowledge, 
there have been only four prior case reports on the 
determination of ECP in either serum or BAL fluid in 
eosinophilic pneumonia and no quantitative data 
on EPX level&in BAL fluid of these patients. Janin 
et al. (5) have reported serum ECP concentrations 
of 28-33 pg 1; ’ in four patients with chronic 
eosinophilic pneumonia. In the same study, it was 
shown that the eosinophil proteins (including ECP 
and MBP) were distributed in different macrophage 
compartments, and that numerous eosinophilic gran- 
ules were present in the BAL fluid. Moreover, these 
features were not observed in four control patients 
with an eosinophilic infiltrate of new origin. Deviller 
et al. (6) have described a patient with an eosinophilic 
pneumonia and a serum ECP level of 36pg 1 - i 
which declined to 14 ,ug 1~ r after 2 months of treat- 
ment. In this patient, a high amount of EPX was 
detected in the urine. Recently, Yoshida et al. (7) 
described a patient with eosinophilic pneumonia with 
a marked ECP concentration (in the circulation 
(318pglll) and BAL fluid (2.7,ugll’). Shijubo 
et al. (8) reported levels of 108.5 f 42.4,ug 1~ ’ in six 
patients with eosinophilic pneumonia. The observed 
serum ECP and EPX levels in the present patient 
were very high as compared to those reported by 
Deviller et al. (1994), and in the same range as 
reported by Yoshida et al. (6) and Shijubo et al. (8). 
The levels in BAL fluid were extremely high as 
compared to most other reports. One other report 
has described high levels of major basic protein in 
pleural fluid recovered from a patient with chronic 
eosinophilic pneumonia (9). 
Since comparable serum and BAL ECP levels were 
observed in the different control populations as 
reported in the literature, it is unlikely that a tech- 
nical problem with either the preservation of the 
samples or the detection method can explain the high 
serum and BAL levels in the present patient. Indeed, 
mean serum ECP levels have been reported to range 
from 5.5 to 32.7 pg 1 - ’ in healthy volunteers (lo-12), 
and mean ECP levels of 21 pug l- ’ in systemic 
sclerosis (11) and 32.7 pg l- ’ in healthy smokers (13) 
have been reported. In asthmatic patients, where 
increased numbers of peripheral eosinophils are 
also observed, there is much discussion about 
whether ECP levels in the serum are consistently 
elevated. Some authors believe that serum ECP 
is not increased in patients with asthma (14), while 
others have observed mean levels as high as 
49.6,ug l- ’ (12). 
The levels of ECP in BAL fluid have been reported 
as ranging from non-detectable to 19 pg 1 - i in non- 
smoking control patients (12,1517), and from 2.4 to 
15.6pg 1-l in asthmatic patients (12,15,18). A mean 
of 7.6pg l- ’ has been reported in patients with 
bacterial pneumonia (19), and a mean of 163 pg l- ’ 
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in patients with ARDS (16), although lavage in this 
latter group was performed with only one 60 ml 
aliquot. 
It is certain that a marked inflammatory reaction 
occurs in eosinophilic pneumonia; Ogushi et al. (20) 
have demonstrated increased contents of PGE, in 
BAL fluid from patients with eosinophilic pneumonia 
as compared to those of normal volunteers, return- 
ing to a normal range after treatment with cortico- 
steroids. Morphological and functional studies of 
eosinophils of patients with eosinophilic pneumonia 
have shown that they differ from normal peripheral 
eosinophils. The alveolar eosinophil population 
found in the BAL fluid is hypodense (21), which 
might be related to the state of activation (22). 
Surface expression of major histocompatibility com- 
plex (MHC) class II surface antigen HLA-Dr (23) 
and surface CD69 antigen (24) have been reported in 
eosinophilic pneumonia. 
The factors responsible for eosinophilic degranula- 
tion have not been identified. In vitro, aggregated 
immunoglobulins, including IgG, IgA and especially 
secretory IgA, induce the eosinophil to release EPX 
(25). Various cytokines which are known to circulate 
in eosinophilic disorders (26) are able to modify 
Ig-induced eosinophil degranulation. The eosinophil 
chemo-attractants IL-5, IL-3 and GM-CSF all 
enhance Ig-induced EPX release, with IL-5 being the 
most potent (27). However, in vivo pathways of 
eosinophil secretion and degranulation might differ 
from the in vitro situation, depending on exposure to 
a particular local micro-environment. 
Eosinophil-derived proteins have been implicated 
in tissue damage. These granular proteins appear to 
mediate damage to different organs including the 
respiratory epithelium in asthma (28) or the blood 
vessels (29). Although tissue-damaging effects of 
eosinophil granular products have been suggested, 
several anti-defence mechanisms might be present 
since clinical recovery is usually complete after 
appropriate treatment. Eosinophilic proteins have, 
for example, been detected in distinct cytoplasmatic 
structures in alveolar macrophages which may 
protect the lung from damage (5). 
Although eosinophilic pneumonia is usually 
responsive to corticosteroids therapy, this responsive- 
ness differs (2), which might be related to hetero- 
genicity of the glucocorticoid receptor on human 
eosinophils (30). In vitro, glucocorticoids are known 
to inhibit chemotaxis of eosinophils (31) but to have 
only a limited effect on eosinophil degranulation (32). 
When the present patient was treated with corti- 
costeroids, circulating ECP and EPX concentrations 
fell markedly and rapidly, and the patient showed a 
corresponding decline in the number of circulating 
peripheral eosinophils. 
The present results support the theory of a high 
degree of activation of eosinophils in eosinophilic 
pneumonia, as has been suggested in the past by the 
presence of hypodense cells; the eosinophil actively 
degranulates its (cytotoxic) proteins. The present 
data also suggest that these eosinophils had released 
their different granular proteins, ECP and EPX, 
during their passage both towards the peripheral 
circulation and from the circulation into the lung. 
Treatment with glucocorticoids lead to a dramatic 
clinical improvement, accompanied by a rapid 
decrease in peripheral eosinophilia and serum levels 
of two of those proteins, ECP and EPX. 
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